AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) has approved JUVMO™ (tavapadon) tablets as the first and only selective D1/D5 receptor agonist for the treatment of ...

Oral medications are often the first treatment for Parkinson’s disease. They work by increasing dopamine levels or mimicking dopamine’s effects, but symptom control may change over time. Infusion ...

FDA gives go-ahead to D1/D5 dopamine agonist tavapadon ...

AbbVie ( ABBV) announced that the U.S. FDA has approved JUVMO (tavapadon) tablets for the treatment of adults with Parkinson's disease, providing a new oral treatment option for a progressive ...

AbbVie’s JUVMO (tavapadon) is the first and only selective D1/D5 receptor agonist approved for adults with Parkinson’s ...

Simon Fraser University researchers are using a new approach to brain imaging that could improve how drugs are prescribed to treat Parkinson's disease. The new study, published in the journal Movement ...

Some people live with essential tremor for years and organically find ways to adapt. Others may begin avoiding activities.

A treatment that uses concentrated sound waves inside the brain has produced rapid improvements in two people with severe ...

For many people who suffer from depression, the condition is not just about feeling down but also about a loss of motivation and difficulty finding pleasure in activities they used to enjoy. A new ...